First Analysis analyst Frank Sparacino upgraded Tabula Rasa HealthCare to Strong Buy and raised his price target for the shares to $84 from $79. The analyst expects the company’s acquisition of PrescribeWellness to have a potential positive impact on revenue and profitability. He raised his estimates and views Tabula Rasa as a leading provider of software and technology-enabled services optimizing medication regimens for patients.
https://thefly.com/landingPageNews.php?id=2876899
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.